泛素-蛋白酶体系统在肝细胞癌中的研究现状及展望

Ubiquitin-proteasome system in hepatocellular carcinoma:current status and future prospectives

肝细胞癌(HCC)作为肝癌最常见的病理类型,具有发病率高,预后差等特点。其进展涉及多种基因组学和表观遗传学改变。泛素-蛋白酶体系统(UPS)是一种选择性蛋白水解系统,参与肝癌的生理和病理过程。以蛋白酶体为靶点的抑制剂在肝癌治疗中显示出良好的治疗效果。因此,全面了解UPS在肝癌中的研究现状以及开发UPS特异性肝癌治疗药物至关重要。本文将结合近年来UPS在肝细胞癌中的研究进展和药物研发,为未来的机制和临床转化研究提供新思路。

Hepatocellular carcinoma,the most common pathological type of hepatocellular carcinoma,is characterized by high incidence and poor prognosis.Its progression involves multiple genomic and epigenetic alterations.The ubiquitin-proteasome system(UPS)is a selective protein hydrolyzing system involved in the physiological and pathological processes of hepatocellular carcinoma.Inhibitors targeting the proteasome have shown promising therapeutic effects in liver cancer treatment.Therefore,it is crucial to have a comprehensive understanding of the current research status of UPS in hepatocellular carcinoma and the development of UPS-specific hepatocellular carcinoma therapeutic agents.In this review,we will combine the research progress and drug development of UPS in hepatocellular carcinoma in recent years to provide new ideas for future mechanism and clinical translational research.